Detection of Elevated Plasma pTau217 in Donated Human Blood Samples: Implications for Blood Transfusion Safety
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 250
- 试验地点
- 1
- 主要终点
- Tau and pTau
研究概览
简要总结
Alzheimer's disease (AD) is characterized by the accumulation of tau pathology, and blood-based biomarkers such as phosphorylated tau-217 (pTau217) have been identified as sensitive and specific predictors of AD risk. Recent studies suggest that individuals with elevated pTau217 levels may be at increased risk for developing AD and cognitive dysfunction. This observational study will examine donated human plasma samples to determine whether some units of donated blood contain abnormally elevated pTau217 concentrations. The overarching goal is to evaluate whether transfusion of blood with higher pTau217 may pose risks to recipients and whether such units should be avoided in clinical use.
详细描述
Study Type:
Observational (Laboratory-based biomarker study; no human intervention)
Study Design:
- Model: Cross-sectional
- Time Perspective: Prospective
- Sample Source: Donated human blood plasma samples obtained through a blood bank
- Enrollment: ~250 plasma samples; ~20 plasma samples of AD patients and ~20 plasma samples of normal control participants, where are purchased from BioIVT (Westbury, NY, USA).
Official Title:
研究设计
- 研究类型
- Observational
- 观察模型
- Other
- 时间视角
- Other
入排标准
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •The plasma sample from donators.
排除标准
- 未提供
结局指标
主要结局
Tau and pTau
时间窗: 6 months.
Concentration of Tau and pTau217 in plasma.
Concentration of pTau217 and Tau
时间窗: 6 months.
We will use nanoneedle technology to measure the concentration of Tau and pTau217 in collected plasma samples from blood donators.
次要结局
未报告次要终点
研究者
Zhongcong Xie
Professor
The University of Texas Health Science Center, Houston